Sign In
Buy NKTX
$2.72
-0.190 (-6.53%)
At Close: Jun 03, 2026
Trial Results Set to Make or Break Small-Cap Pharma Stocks
04:15pm, Wednesday, 06'th Jul 2022
One analyst is putting the odds at three to one that tests of a Karuna Therapeutics Inc. ( KRTX , Financial) schizophrenia drug will meet study objectives, paving the way to Food and Drug Administrati
Nkarta Stock a Bargain Compared to Fate Therapeutics
05:24pm, Wednesday, 08'th Jun 2022
Investors who like Fate Therapeutics Inc. ( FATE , Financial) should love Nkarta Inc. ( NKTX , Financial).
Nkarta to Participate at Upcoming Investor Conference
07:02am, Tuesday, 31'st May 2022
SOUTH SAN FRANCISCO, Calif., May 31, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today a
Nkarta: A Promising Natural Killer Cell Play
03:14pm, Friday, 20'th May 2022
The market has favorably appreciated Nkarta's recent readout of its NKX101 and NKX019 drug candidates, with the share price more than doubling. I see a huge disconnect between analyst targets and the
What Makes Nkarta, Inc. (NKTX) a New Buy Stock
01:32pm, Wednesday, 18'th May 2022
Nkarta, Inc. (NKTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Up 131% in a Day, Is This Hot Stock a Buy?
10:18am, Thursday, 28'th Apr 2022
Some of its early clinical data look much better than expected.
Nkarta Scores Huge Gain on Cancer Treatment Results
05:04pm, Monday, 25'th Apr 2022
Bargain hunters may want to feast their eyes on a South San Francisco-based biotech focusing on cancer treatments.
Here is why Nkarta is 40% up
12:51pm, Monday, 25'th Apr 2022
Nkarta Inc. (NASDAQ: NKTX) is up 40% after announcing positive preliminary Phase 1 findings from its dose-finding trials of NKX101 and NKX019 in hematological malignancies. NKX101 and NKX019 are two l
Why Is Nkarta (NKTX) Stock Soaring 90% Today?
11:39am, Monday, 25'th Apr 2022
Nkarta (NKTX) stock is rocketing higher on Monday after the company released preliminary data from a Phase 1 clinical trial. The post Why Is Nkarta (NKTX) Stock Soaring 90% Today?
Investors Cheer Nkarta's First NK Cell Data With Multiple Complete Responses
10:57am, Monday, 25'th Apr 2022
Nkarta Inc (NASDAQ: NKTX) has revealed the first human results from its two lead off-the-shelf NK cell therapies, with the high-dose regimens exhibiting multiple complete responses in blood cancer
Nkarta stock skyrockets on heavy volume after upbeat results from cancer-treatment trial
10:49am, Monday, 25'th Apr 2022
Shares of Nkarta Inc. NKTX, +95.82% skyrocketed 92.8% in very active morning trading, enough to make the stock the biggest gainer and most active listed on major U.S. exchanges, after the biopharmaceu
Struggling Biopharma Stock Blasts Higher After Upbeat Data
10:35am, Monday, 25'th Apr 2022
Biopharmaceutical stock Nkarta Inc (NASDAQ:NKTX) is skyrocketing today, up 91.4% at $14.87 at last check, after the company announced positive preliminary data for two of its experimental cell therapy
Why Nkarta Stock Is Soaring Today
09:06am, Monday, 25'th Apr 2022
Nkarta Inc (NASDAQ: NKTX) shares are trading higher Monday morning after the company announced positive preliminary Phase 1 data from independent dose finding studies. The positive data was for the
Nkarta's stock jumps 42% after announcing positive Phase 1 data for experimental CAR-T therapies
08:04am, Monday, 25'th Apr 2022
Shares of Nkarta Inc. NKTX, -2.51% soared 42.7% in premarket trading on Monday after the company reported positive Phase 1 clinical data for two experimental CAR-T therapies. Three of five patients wi
Nkarta to Host Conference Call Highlighting Preliminary Clinical Data from Two Lead NK Cell Therapy Candidates
04:10pm, Friday, 22'nd Apr 2022
Call scheduled for Monday, April 25, 2022 8:00 a.m. ET
